SEC Tracker
Get the app

Vera Therapeutics VERA

Vera Therapeutics reported a $93.71 million net loss

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $10.28 million for the three months ended Sep 30, 2026
  2. Net loss of $93.71 million for the three months ended Sep 30, 2026
  3. Cash and equivalents of $55.32 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Vera Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ani Pharmaceuticals ANIP public float $1.3B, Jun 30, 2025
  2. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025
  3. Travere Therapeutics TVTX public float $1.3B, Jun 30, 2025
  4. Innoviva INVA public float $1.3B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.